Independent committee says Praxis' tremor drug trial unlikely to meet main goal-March 2024-www.financetom.com

Independent committee says Praxis' tremor drug trial unlikely to meet main goal

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Independent committee says Praxis' tremor drug trial unlikely to meet main goal

Feb 28, 2025 5:29 AM

Feb 28 (Reuters) - Praxis Precision Medicines ( PRAX )

said on Friday an independent committee had recommended its

tremor drug trial be stopped for futility, as it was unlikely to

meet its main goal.

Previous page： Grid Dynamics Holdings Insider Sold Shares Worth $1,044,000, According to a Recent SEC Filing Next page： JPMorgan CEO Jamie Dimon's pay set at $39 mln for 2024

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Grid Dynamics Holdings Insider Sold Shares Worth $1,044,000, According to a Recent SEC Filing

Jan 23, 2025

04:21 PM EST, 01/23/2025 (MT Newswires) -- Leonard Livschitz, Director, CEO, on January 21, 2025, sold 50,000 shares in Grid Dynamics Holdings ( GDYN ) for $1,044,000. Following the Form 4 filing with the SEC, Livschitz has control over a total of 3,046,600 shares of the company, with 3,041,906 shares held directly and 4,694 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1743725/000089914025000080/xslF345X05/form4.xml ...

JPMorgan CEO Jamie Dimon's pay set at $39 mln for 2024

Jan 23, 2025

Jan 23 (Reuters) - JPMorgan Chase ( JPM ) said on Thursday CEO Jamie Dimon's 2024 compensation has been set at $39 million. (Reporting by Pritam Biswas in Bengaluru) ...

East West Bancorp Q4 Adjusted Earnings, Revenue Rise; Share Buyback, Dividend Boosted

Jan 23, 2025

04:24 PM EST, 01/23/2025 (MT Newswires) -- East West Bancorp ( EWBC ) reported Q4 adjusted diluted earnings late Thursday of $2.08, up from $2 a year earlier. Analysts polled by FactSet expected $2.12. Revenue in the three months ended Dec. 31, expressed as a sum of total net interest income and noninterest income, rose to $675.8 million from $654.7...

Harmony Biosciences Holdings Insider Sold Shares Worth $774,245, According to a Recent SEC Filing

Jan 23, 2025

04:21 PM EST, 01/23/2025 (MT Newswires) -- Jeffrey M. Dayno, Director, President, and CEO, on January 21, 2025, sold 19,293 shares in Harmony Biosciences Holdings ( HRMY ) for $774,245. SEC Filing: https://www.sec.gov/Archives/edgar/data/1802665/000141588925001931/xslF345X05/form4-01232025_090139.xml ...